How Can We Bring Innovative Research to People Faster?
This question took center stage at Helmholtz Munich's Conference Center, where researchers from all eight German Centers for Health Research (DZG) represented in the Munich region came together with guests from politics, industry, academia, and clinical practice to discuss achievements, challenges, and the future of health research.
A Message from Germany's Federal Minister of Research
In a video address, Federal Minister of Research Dorothee Bär highlighted the important role of the DZG network in strengthening Germany's position as a global research hub.
Munich holds a unique position within this landscape: it is the only region where all eight German Centers for Health Research are represented. Together, they cover the full spectrum of major health challenges, including mental health, pediatric diseases, cardiovascular diseases, infectious diseases, neurodegenerative and respiratory disorders, cancer, and diabetes.
Shaping the Future of Lung Research
At CPC-M, the Munich site of the German Center for Lung Research (DZL), future efforts will place a particular emphasis on artificial intelligence and virtual lung models. According to CPC-M Director Önder Yildirim, CPC-M is exceptionally well positioned for this next phase, with an impressive network of 65 principal investigators driving innovation since 2026.
Looking beyond individual research areas, Stefanie Dimmeler, Chair of the DZG Board, outlined a broader vision for collaboration across the DZG network. Her priorities include stronger connectivity between centers, faster translation of scientific discoveries into clinical practice, and a greater focus on innovation.
One tangible example is the planned launch of a patient study portal on the DZG website later this year. The platform will serve as a central access point for patients seeking information about clinical trials across all DZG centers.
Spotlight on "AI Meets Drug Repurposing"
A dedicated session brought together experts from academia and industry to explore how existing medications can be repurposed for entirely different diseases and how artificial intelligence can accelerate this process.
Kamyar Hadian from CPC-M presented an inspiring example in the field of rare diseases. Within just a few years, his team succeeded in transforming an existing immunosuppressive drug into a promising therapeutic candidate for childhood interstitial lung disease (chILD), a severe form of pediatric lung fibrosis for which no effective treatment currently exists.
Recognizing Young Scientific Talent
Congratulations to Alexandra Lenoir and Lena Lagally from the research group of CPC-M scientist Bianca Schaub. Their project investigating molecular mechanisms underlying asthma was recognized with a poster award.
Conclusion
The DZG Munich Day once again demonstrated that the major challenges facing modern medicine can only be addressed through strong partnerships, interdisciplinary collaboration, and the rapid translation of scientific discoveries into real-world healthcare solutions.
This version reads more naturally for an international scientific audience and has a slightly more journalistic, story-driven style while preserving all key messages.